SAB Biotherapeutics (SABS) EPS (Weighted Average and Diluted) (2021 - 2026)
SAB Biotherapeutics (SABS) reported EPS (Weighted Average and Diluted) of -$0.35 for Q1 2026, up 37.5% on a YoY basis from -$0.25 in Q1 2025, and up 23.91% quarter-over-quarter from -$0.46 in Q4 2025.
SAB Biotherapeutics (SABS) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
SAB Biotherapeutics has reported EPS (Weighted Average and Diluted) for 6 years, with the latest figure at -$0.35 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 37.5% year-over-year to -$0.35; the trailing twelve-month figure through Mar 2026 stood at -$2.11 (up 42.97% YoY), and the FY2025 full-year result was -$0.79, up 78.53% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.35, up from -$0.46 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $0.02 in Q1 2022, with the low at -$3.85 in Q4 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.94 across 5 years, with a median of -$0.79 in 2024.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) slumped 7400.0% — and 2025, when it jumped 81.25%.
- SAB Biotherapeutics' EPS (Weighted Average and Diluted) stood at -$1.81 in 2022, then slumped by 112.8% to -$3.85 in 2023, then jumped by 68.05% to -$1.23 in 2024, then jumped by 62.6% to -$0.46 in 2025, then rose by 23.91% to -$0.35 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.35 (Q1 2026), -$0.46 (Q4 2025), and -$0.21 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | -0.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.35 |
| Dec 31, 2025 | -0.46 |
| Sep 30, 2025 | -0.21 |
| Jun 30, 2025 | -1.09 |
| Mar 31, 2025 | -0.56 |
| Dec 31, 2024 | -1.23 |
| Sep 30, 2024 | -1.12 |
| Jun 30, 2024 | -0.79 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | -3.85 |
| Sep 30, 2023 | -0.97 |
| Jun 30, 2023 | -1.36 |
| Mar 31, 2023 | -1.46 |
| Dec 31, 2022 | -1.81 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.11 |
| Mar 31, 2022 | 0.02 |
| Dec 31, 2021 | -0.41 |
| Sep 30, 2021 | -0.16 |
| Jun 30, 2021 | -0.11 |